Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Publikováno v:
BMC Cancer
Background In the past decades, mortality of female gender related cancers declined in Switzerland and other developed countries. Differences in the decrease and in spatial patterns within Switzerland have been reported according to urbanisation and
Autor:
Riikka Nurminen, Johanna Schleutker, Heli Nevanlinna, Liisa M. Pelttari, Lauri A. Aaltonen, Alexandra E. Gylfe
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 552 (2012)
BMC Cancer
BMC Cancer
Background Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not
Publikováno v:
Breast Cancer Research
Introduction Mutations in BRCA1, BRCA2, ATM, TP53, CHK2 and PTEN account for many, but not all, multiple-case breast and ovarian cancer families. The histone acetyltransferase gene EP300 may function as a tumour suppressor gene because it is sometime
Autor:
Letitia D. Smith, Irene L. Andrulis, Ee Ming Wong, Andrew K. Godwin, Andrea Tesoriero, Esther M. John, Mary B. Daly, Mary Beth Terry, Ruby T. Senie, Stephen B. Fox, Melissa C. Southey, David E. Goldgar, Frances P. O'Malley, Graham G. Giles, Saundra S. Buys, Regina M. Santella, Hilmi Ozcelik, John L. Hopper, Anna Marie Mulligan, Susan J. Ramus
Publikováno v:
Breast Cancer Research : BCR
Introduction: Selecting women affected with breast cancer who are most likely to carry a germline mutation in BRCA1 and applying the most appropriate test methodology remains challenging for cancer genetics services. We sought to test the value of se
Autor:
Dagnija Kalniete, Jekaterina Zestkova, Arvids Irmejs, Janis Gardovskis, Karina Aksenoka, Andris Gardovskis, Dace Berzina, Miki Nakazawa-Miklasevica, Edvins Miklasevics
Publikováno v:
BMC Medical Genetics
Background The estimated ratio of hereditary breast/ovarian cancer (HBOC) based on family history is 1.5% in Latvia. This is significantly lower than the European average of 5–10%. Molecular markers like mutations and SNPs can help distinguish HBOC
Autor:
David B. Young, Amanda B. Spurdle, Graham J. Mann, Gulietta M. Pupo, Georgia Chenevix-Trench, Felicity Lose, Carolyn J. Brown, Kum Kum Khanna, Jeremy Arnold
Publikováno v:
Breast cancer research : BCR
Introduction BRCA1 is involved in numerous essential processes in the cell, and the effects of BRCA1 dysfunction in breast cancer carcinogenesis are well described. Many of the breast cancer susceptibility genes such as BRCA2, p53, ATM, CHEK2, and BR
Autor:
Friedman, E, Kotsopoulos, J, Lubinski, J, Lynch, Ht, Ghadirian, P, Neuhausen, Sl, Isaacs, C, Weber, B, Foulkes, Wd, Moller, P, Rosen, B, Kim Sing, C, Gershoni Baruch, R, Ainsworth, P, Daly, M, Tung, N, Eisen, A, Olopade, Oi, Karlan, B, Saal, Hm, Garber, Je, Rennert, G, Gilchrist, D, Eng, C, Offit, K, Osborne, M, Sun, P, Narod, Sa, Mclennan, J, Fishman, D, Merajver, S, Mckinnon, W, Wood, M, Chudley, A, Warner, E, Weitzel, J, Evans, G, Lemire, E, Olsson, H, Meschino, W, Provencher, D, Mills, G, Pasche, B, Fallen, T, Pasini, Barbara, Bellati, C, Couch, F, Wagner, T, Kipper, L, Steele, P.
Publikováno v:
Breast Cancer Research
Introduction BRCA1 and BRCA2 mutation carriers are at increased risk for developing both breast and ovarian cancer. It has been suggested that carriers of BRCA1/2 mutations may also be at increased risk of having recurrent (three or more) miscarriage
Autor:
Elton Rexhepaj, Darran P. O'Connor, Donal J. Brennan, Mathias Uhlén, Fredrik Pontén, Michael E. Foley, Jenny Brändstedt, Colm O'Herlihy, Karin Jirström, William M. Gallagher
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 125 (2010)
BMC Cancer; 10 (2010)
BMC Cancer, Vol 10, Iss 1, p 125 (2010)
BMC Cancer; 10 (2010)
Background Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a goo
Autor:
Mathias Krockenberger, Michaela Kapp, Arnd Honig, Lorenz Rieger, Matthias Eck, Ulrike Kämmerer, Johannes Dietl
Publikováno v:
BMC Cancer, Vol 6, Iss 1, p 199 (2006)
BMC Cancer
BMC Cancer
Background Tartrate-resistant acid phosphatase (TRAP) is a metalloprotein enzyme that belongs to the acid phosphatases and is known to be expressed by osteoclasts. It has already been investigated as a marker of bone metastases in cancer patients. In
Autor:
Janez Zgajnar, Jacques De Greve, Guido Goelen, Erik Teugels, Mateja Krajc, Srdjan Novaković, Nikola Besic, Marko Hočevar
Publikováno v:
BMC Medical Genetics, Vol 9, Iss 1, p 83 (2008)
Vrije Universiteit Brussel
BMC Medical Genetics
Vrije Universiteit Brussel
BMC Medical Genetics
Background Both recurrent and population specific mutations have been found in different areas of the world and more specifically in ethnically defined or isolated populations. The population of Slovenia has over several centuries undergone limited m